PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
February 13, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative...
PetVivo Reports Third Quarter of Fiscal 2024 Financial Results
February 12, 2024 16:00 ET
|
PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the...
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
February 07, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
February 06, 2024 12:37 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology
January 31, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
January 25, 2024 01:00 ET
|
BioSenic
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une...
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
January 25, 2024 01:00 ET
|
BioSenic
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
January 23, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Osteoporosis Drugs Market Size Worth USD 20.53 Billion in 2032 | Emergen Research
January 18, 2024 10:15 ET
|
Emergen Research
Vancouver, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The global osteoporosis drugs market size was USD 13.06 billion in 2022 and is expected to register a revenue CAGR of 4.7% during the forecast period....
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
January 17, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel,...